Literature DB >> 47335

Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thryoid carcinoma.

G W Sizemore, H Hpeath, J M Larson.   

Abstract

Marked discrepancies (values up to four times higher in on assay than in the other) were observed when the plasma concentration of immunoreactive human calcitonin (iCT) was measured by two radioimm8noassays in 18 patients with medullary thyroid carcinoma. The two antisera used had different binding affinities for the NH2- and COOH-terminal regions of synthetic calcitonin monomer (CT-1-32). Except for this difference, the assays were identical and reacted equally with CT 1-32. Plasma samples from patients with medullary thyroid carcinoma were gel filtered on columns of Bio-Gel P-150, and the immunoreactivity in column effuent fractions was measured with both assays. The one utilizing the antiserum with prominent NH2-terminal binding affinity (and giving higher iCT values) recognized at least five molecular species that eluted with or before CT 1-32. The other assay, utilizing the antiserum with a COOH-terminal binding affinity, recognized two fo these molecular species-one eluting with CT 1-32 and the other in a position consistent with a dimer. A mixture of athreotic asthma and added CT 1-32 contained a single immunologic species that was recoqnized equally by both antisera. No forms smaller than CT 1-32 were detected in any study. The results suggest that iCT circulating in the plasma of patients with medullary thryoid carcinoma is hetergeneous. The absolute iCT concentration measured by radioimmunoassays depends on recognition of these distinct molecular species as well as on the specific binding affinities of the antiserum used to detect them. These observations may partially explain the variations among iCT values reported by different laboratories.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 47335      PMCID: PMC301858          DOI: 10.1172/JCI108012

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Radioimmunometric assay for human calcitonin.

Authors:  R D Hesch; J S Woodhead; M Hüfner; F M Dietrich
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1973

2.  Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.

Authors:  A L Steiner; A D Goodman; S R Powers
Journal:  Medicine (Baltimore)       Date:  1968-09       Impact factor: 1.889

3.  Influence of immunoheterogeneity of circulating parathyroid hormone on results of radioimmunoassays of serum in man.

Authors:  C D Arnaud; R S Goldsmith; P J Bordier; G W Sizemore
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

4.  [Extraction and concentration of human plasma calcitonin using coupled antibodies on a solid support].

Authors:  M S Moukhtar; A Jullienne; D Tharaud; J Taboulet; G Milhaud
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1973-06-25

5.  Human calcitonin radioimmunoassay in normal and pathological conditions.

Authors:  G Heynen; P Franchimont
Journal:  Eur J Clin Invest       Date:  1974-06       Impact factor: 4.686

6.  Relations of calcitonin and gastrin in the Zollinger-Ellison syndrome and medullary carcinoma of the thyroid.

Authors:  G W Sizemore; V L Go; E L Kaplan; L J Sanzenbacher; K H Holtermuller; C D Arnaud
Journal:  N Engl J Med       Date:  1973-03-29       Impact factor: 91.245

7.  Immunochemical studies on human calcitonin M leading to information on the shape of the molecule.

Authors:  P G Byfield; M B Clark; K Turner; G V Foster; I MacIntyre
Journal:  Biochem J       Date:  1972-03       Impact factor: 3.857

8.  Immunoassay of thyrocalcitonin. I. The method and its serological specificity.

Authors:  A H Tashjian
Journal:  Endocrinology       Date:  1969-01       Impact factor: 4.736

9.  Radioimmunoassay of calcitonin in human plasma.

Authors:  O L Silva; R H Snider; K L Becker
Journal:  Clin Chem       Date:  1974-03       Impact factor: 8.327

10.  Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism.

Authors:  R C Benson; B L Riggs; B M Pickard; C D Arnaud
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more
  14 in total

1.  Calcitonin heterogeneity: in vivo and in vitro studies.

Authors:  B A Roos; J G Parthemore; J C Lee; L J Deftos
Journal:  Calcif Tissue Res       Date:  1977-05

2.  Plasma calcitonin in normal man. Differences between men and women.

Authors:  H Heath; G W Sizemore
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  The regulation of calcitonin in normal human plasma as assessed by immunoprecipitation and immunoextraction.

Authors:  J G Parthemore; L J Deftos; D Bronzert
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

4.  Purification and partial characterization of high-molecular-weight forms of ectopic calcitonin from a human bronchial carcinoma cell line.

Authors:  J Lumsden; J Ham; M L Ellison
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

Review 5.  Calcitonin: perspectives in current concepts.

Authors:  H J Wolfe
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

6.  Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor.

Authors:  S Del Prato; A Rovira; P Tessari; A Avogaro; R Nosadini; I Valverde; R Trevisan; A Tiengo
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

7.  Characterization of the immunochemical forms of calcitonin released by a medullary thyroid carcinoma in tissue culture.

Authors:  D Goltzman; A S Tischler
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

8.  Tumour calcitonin. Interaction with specific calcitonin receptors.

Authors:  J Ham; M L Ellison; J Lumsden
Journal:  Biochem J       Date:  1980-09-15       Impact factor: 3.857

9.  Prospective evaluation of some candidate tumor markers in the diagnosis of pancreatic cancer.

Authors:  C R Mackie; A R Moossa; V L Go; G Noble; G Sizemore; M J Cooper; R A Wood; A W Hall; T Waldmann; F Gelder; A H Rubenstein
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

10.  Comparison of the effects of pentagastrin and meal-stimulated gastrin on plasma calcitonin in normal man.

Authors:  C Owyang; H Heath; G W Sizemore; V L Go
Journal:  Am J Dig Dis       Date:  1978-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.